Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Catalyst Biosciences management to meet virtually with Piper Sandler » 11:24
05/27/21
05/27
11:24
05/27/21
11:24
CBIO

Catalyst Biosciences

$4.24 /

+0.07 (+1.68%)

Virtual Meeting to be…

Virtual Meeting to be held on May 27 hosted by Piper Sandler.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.24 /

+0.07 (+1.68%)

CBIO Catalyst Biosciences
$4.24 /

+0.07 (+1.68%)

04/29/21 Raymond James
Catalyst Biosciences assumed with an Outperform at Raymond James
04/28/21 Piper Sandler
Catalyst Biosciences should be bought 'right here,' says Piper Sandler
03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
CBIO Catalyst Biosciences
$4.24 /

+0.07 (+1.68%)

  • 27
    Jan
  • 18
    Jun
Hot Stocks
Catalyst Biosciences doses first patient in Phase 1/2 study of MAA-202 » 08:21
05/18/21
05/18
08:21
05/18/21
08:21
CBIO

Catalyst Biosciences

$4.18 /

+0.005 (+0.12%)

Catalyst Biosciences…

Catalyst Biosciences announced the initiation of dosing in the Company's Phase 1/2 study of marzeptacog alfa- known as "MarzAA." MarzAA is a subcutaneously administered next-generation engineered coagulation Factor VIIa. MAA-202 is a Phase 1/2 open-label study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and efficacy of SQ MarzAA for treatment of bleeding in FVII deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients receiving Hemlibra prophylaxis. This study, along with Catalyst's ongoing Phase 3 study MAA-304 evaluating MarzAA for the treatment of bleeding episodes in patients with Hemophilia A or B with inhibitors, is a key part of the Company's strategy to realize the full potential of MarzAA to improve the lives of patients with inherited bleeding disorders.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.18 /

+0.005 (+0.12%)

CBIO Catalyst Biosciences
$4.18 /

+0.005 (+0.12%)

04/29/21 Raymond James
Catalyst Biosciences assumed with an Outperform at Raymond James
04/28/21 Piper Sandler
Catalyst Biosciences should be bought 'right here,' says Piper Sandler
03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
CBIO Catalyst Biosciences
$4.18 /

+0.005 (+0.12%)

  • 27
    Jan
  • 18
    Jun
Over a month ago
Conference/Events
Catalyst Biosciences participates in a conference call with Truist » 12:25
05/17/21
05/17
12:25
05/17/21
12:25
CBIO

Catalyst Biosciences

$4.17 /

+ (+0.00%)

Conference call with…

Conference call with management will be held on May 17 at 1 pm hosted by Truist.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.17 /

+ (+0.00%)

CBIO Catalyst Biosciences
$4.17 /

+ (+0.00%)

04/29/21 Raymond James
Catalyst Biosciences assumed with an Outperform at Raymond James
04/28/21 Piper Sandler
Catalyst Biosciences should be bought 'right here,' says Piper Sandler
03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
CBIO Catalyst Biosciences
$4.17 /

+ (+0.00%)

  • 27
    Jan
  • 18
    Jun
Conference/Events
Catalyst Biosciences participates in a conference call with Truist » 04:55
05/17/21
05/17
04:55
05/17/21
04:55
CBIO

Catalyst Biosciences

$4.17 /

-0.11 (-2.57%)

Conference call with…

Conference call with management will be held on May 17 at 1 pm hosted by Truist.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.17 /

-0.11 (-2.57%)

CBIO Catalyst Biosciences
$4.17 /

-0.11 (-2.57%)

04/29/21 Raymond James
Catalyst Biosciences assumed with an Outperform at Raymond James
04/28/21 Piper Sandler
Catalyst Biosciences should be bought 'right here,' says Piper Sandler
03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
CBIO Catalyst Biosciences
$4.17 /

-0.11 (-2.57%)

  • 27
    Jan
  • 18
    Jun
Conference/Events
Catalyst Biosciences participates in a conference call with Truist » 11:50
05/11/21
05/11
11:50
05/11/21
11:50
CBIO

Catalyst Biosciences

$4.49 /

-0.01 (-0.22%)

Conference call with…

Conference call with management will be held on May 17 at 1 pm hosted by Truist.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.49 /

-0.01 (-0.22%)

CBIO Catalyst Biosciences
$4.49 /

-0.01 (-0.22%)

04/29/21 Raymond James
Catalyst Biosciences assumed with an Outperform at Raymond James
04/28/21 Piper Sandler
Catalyst Biosciences should be bought 'right here,' says Piper Sandler
03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
CBIO Catalyst Biosciences
$4.49 /

-0.01 (-0.22%)

  • 27
    Jan
  • 18
    Jun
Earnings
Catalyst Biosciences reports Q1 EPS (79c), consensus (58c) » 08:04
05/06/21
05/06
08:04
05/06/21
08:04
CBIO

Catalyst Biosciences

$4.62 /

-0.1 (-2.12%)

Reports Q1 revenue…

Reports Q1 revenue $1.47M, consensus $800,000. "We made significant progress across our Protease Medicines platform, specifically in our complement and hemostasis programs. We are preparing to initiate an observational trial in patients who have diseases related to CFI deficiency in mid-year 2021 to support our SQ enhanced CFI development candidate CB 4332 that will enter the clinic in 2022," said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. "In hemostasis, we dosed our first subject in the Crimson 1 Phase 3 registrational study of MarzAA, our next generation SQ FVIIa, in hemophilia A or B with inhibitors and are enrolling patients in a Phase 1/2 trial in other rare bleeding disorders."

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.62 /

-0.1 (-2.12%)

CBIO Catalyst Biosciences
$4.62 /

-0.1 (-2.12%)

04/29/21 Raymond James
Catalyst Biosciences assumed with an Outperform at Raymond James
04/28/21 Piper Sandler
Catalyst Biosciences should be bought 'right here,' says Piper Sandler
03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
CBIO Catalyst Biosciences
$4.62 /

-0.1 (-2.12%)

  • 27
    Jan
  • 18
    Jun
Hot Stocks
Catalyst Biosciences announces first patient dosed in Phase 3 SQ MarzAA study » 08:10
05/05/21
05/05
08:10
05/05/21
08:10
CBIO

Catalyst Biosciences

$4.71 /

-0.29 (-5.80%)

Catalyst Biosciences…

Catalyst Biosciences announced the dosing of the first patient in the Crimson 1 Study, the Company's Phase 3 registration trial of Marzeptacog alfa - or MarzAA, the Company's subcutaneously administered next-generation engineered recombinant coagulation Factor VIIa. "Dosing the first patient in our pivotal Phase 3 study of MarzAA is an important milestone for Catalyst given the significant challenges encountered in conducting clinical trials during the ongoing global Covid-19 pandemic," said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. "MarzAA is the only SQ-delivered therapy in development for the episodic treatment of bleeding events and if successful, could fundamentally change patients' lives. We look forward to providing further updates on the MAA-304 study, the associated Phase 1/2 study in other rare bleeding disorders, and in our growing complement pipeline later this year."Crimson 1 is an open-label, global, multi-center, randomized, cross-over study, designed to evaluate the safety and efficacy of SQ MarzAA for episodic treatment of spontaneous or traumatic bleeding episodes, in adults and adolescents with congenital Hemophilia A or B with inhibitors, compared with standard of care. The study will assess the effectiveness of SQ MarzAA, using up to three doses to treat a bleeding episode, compared with IV FEIBA or up to three doses of IV rFVIIa. Catalyst anticipates the submission of its first report to the Data and Safety Monitoring Board in 2021.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.71 /

-0.29 (-5.80%)

CBIO Catalyst Biosciences
$4.71 /

-0.29 (-5.80%)

04/29/21 Raymond James
Catalyst Biosciences assumed with an Outperform at Raymond James
04/28/21 Piper Sandler
Catalyst Biosciences should be bought 'right here,' says Piper Sandler
03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
CBIO Catalyst Biosciences
$4.71 /

-0.29 (-5.80%)

  • 27
    Jan
  • 18
    Jun
Initiation
Catalyst Biosciences assumed with an Outperform at Raymond James » 07:22
04/29/21
04/29
07:22
04/29/21
07:22
CBIO

Catalyst Biosciences

$5.11 /

+0.15 (+3.02%)

Raymond James analyst…

Raymond James analyst Timur Ivannikov assumed coverage of Catalyst Biosciences with an Outperform rating with a price target of $19, up from $18. The analyst thinks MarzAA will work in the ongoing Phase 3 study, which is expected to read out ~mid-2022, and while he thinks DalcA is a promising asset, without a clear path forward, is assigning relatively little value, Ivannikov tells investors in a research note.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$5.11 /

+0.15 (+3.02%)

CBIO Catalyst Biosciences
$5.11 /

+0.15 (+3.02%)

04/28/21 Piper Sandler
Catalyst Biosciences should be bought 'right here,' says Piper Sandler
03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Piper Sandler
Catalyst Biosciences initiated with an Overweight at Piper Sandler
CBIO Catalyst Biosciences
$5.11 /

+0.15 (+3.02%)

  • 27
    Jan
  • 18
    Jun
Recommendations
Catalyst Biosciences should be bought 'right here,' says Piper Sandler » 04:55
04/28/21
04/28
04:55
04/28/21
04:55
CBIO

Catalyst Biosciences

$4.95 /

-0.1 (-1.98%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Catalyst Biosciences with a $15 price target after taking over coverage of the name. While Catalyst's core platform, protease engineering, "may not check all the boxes common to some of the more in-fashion names," MarzAA and the company's economics on CB 2782-PEG by themselves "could justify many multiples from the company's current market cap," Raymond tells investors in a research note. When combined with a "novel complement portfolio with numerous derisking data events on tap," it is hard to find "an instance when the market has so completely discounted such value," says the analyst. He would be a buyer of the stock "right here."

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.95 /

-0.1 (-1.98%)

CBIO Catalyst Biosciences
$4.95 /

-0.1 (-1.98%)

03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Piper Sandler
Catalyst Biosciences initiated with an Overweight at Piper Sandler
02/09/21 JonesTrading
Catalyst Biosciences assumed with a Buy at JonesTrading
CBIO Catalyst Biosciences
$4.95 /

-0.1 (-1.98%)

  • 27
    Jan
  • 18
    Jun
Conference/Events
Catalyst Biosciences management to meet virtually with Piper Sandler » 08:44
04/20/21
04/20
08:44
04/20/21
08:44
CBIO

Catalyst Biosciences

$4.56 /

-0.205 (-4.30%)

Virtual Meeting to be…

Virtual Meeting to be held on April 20 hosted by Piper Sandler.

ShowHide Related Items >><<
CBIO Catalyst Biosciences
$4.56 /

-0.205 (-4.30%)

CBIO Catalyst Biosciences
$4.56 /

-0.205 (-4.30%)

03/04/21 Piper Sandler
Catalyst Biosciences' momentum to build throughout 2021, says Piper Sandler
02/10/21
Fly Intel: Top five analyst initiations
02/10/21 Piper Sandler
Catalyst Biosciences initiated with an Overweight at Piper Sandler
02/09/21 JonesTrading
Catalyst Biosciences assumed with a Buy at JonesTrading
CBIO Catalyst Biosciences
$4.56 /

-0.205 (-4.30%)

  • 27
    Jan
  • 18
    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.